Latest News in the pharma Industry

Research & Development

Apta Biosciences awarded H2020 EU grant

Apta Biosciences awarded H2020 EU grant

4 Nov 2015

Company will use the grant to incorporate Seligo technology into next generation antibiotics and infectious disease therapeutics.

Read more 
FDA requests further data for approval of Epigenomics' blood based colorectal cancer screening test

FDA requests further data for approval of Epigenomics' blood based colorectal cancer screening test

4 Nov 2015

Epigenomics adjusts 2015 outlook after FDA response letter.

Read more 
GSK and Merck to study immunotherapy combination as potential cancer treatment

GSK and Merck to study immunotherapy combination as potential cancer treatment

3 Nov 2015

Phase I first-in-human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab).

Read more 
Sanofi and BioNTech announce cancer immunotherapy collaboration and license agreement

Sanofi and BioNTech announce cancer immunotherapy collaboration and license agreement

3 Nov 2015

The agreement will leverage the scientific expertise of the two organizations to discover and develop up to five cancer immunotherapies.

Read more 
First investigational all injectable long acting HIV combination regimen study results at 32 weeks announced

First investigational all injectable long acting HIV combination regimen study results at 32 weeks announced

3 Nov 2015

Injectable combinations once every 4 or 8 weeks show comparable efficacy versus daily oral combination therapy.

Read more 
Eli Lilly announces expansion of Indianapolis R&D headquarters

Eli Lilly announces expansion of Indianapolis R&D headquarters

2 Nov 2015

New building to feature collaboration-focused workspace.

Read more 
Regeneron’s Eylea Injection for the treatment of visual impairment secondary to myopic CNV gains EU approval

Regeneron’s Eylea Injection for the treatment of visual impairment secondary to myopic CNV gains EU approval

1 Nov 2015

Eyela already approved in the EU for neovasular (wet) age-related macular degeneration.

Read more 
BMS receives approval from FDA for Yervoy (ipilimumab) as adjuvant treatment for fully resected Stage III melanoma

BMS receives approval from FDA for Yervoy (ipilimumab) as adjuvant treatment for fully resected Stage III melanoma

29 Oct 2015

First company to demonstrate the potential of an immune checkpoint inhibitor in the adjuvant treatment for these patients.

Read more 
Ashland presents science-based strategy to enhance pharmaceutical formulation quality and advance drug delivery

Ashland presents science-based strategy to enhance pharmaceutical formulation quality and advance drug delivery

29 Oct 2015

A scientific approach to select polymer excipients that will better serve the pharmaceutical industry.

Read more 
Shire's OPUS-3 Phase II trial with lifitegrast meets primary and key secondary endpoints, significantly reducing patient-reported symptoms for dry eye disease

Shire's OPUS-3 Phase II trial with lifitegrast meets primary and key secondary endpoints, significantly reducing patient-reported symptoms for dry eye disease

29 Oct 2015

Data to support lifitegrast FDA resubmission in Q1 2016; plans on track for potential 2016 launch.

Read more 
Affinivax to collaboration with ClearPath and Astellas to develop vaccines to prevent nosocomial infections

Affinivax to collaboration with ClearPath and Astellas to develop vaccines to prevent nosocomial infections

28 Oct 2015

Collaboration will utilize Affinivax’s novel MAPS Vaccine Technology Platform.

Read more 
Agilent Technologies introduces industry’s most sensitive GC/MSD system

Agilent Technologies introduces industry’s most sensitive GC/MSD system

27 Oct 2015

Pollutants and contaminants can now be detected at previously undetectable levels.

Read more